α1-adrenergic receptor antagonists induce production of IL-18 and expression of ICAM-1 and CD40 in human monocytes

Journal of Immunotherapy

Volumn 28, Issue 1, 2005, Pages 40-43

  Takahashi, Hideo Kohka ^a   Iwagaki, Hiromi ^a   Tamura, Ryuji ^a   Katsuno, Goutarou ^a   Xue, Dong ^a   Sugita, Sachi ^a   Mori, Shuji ^a   Yoshino, Tadashi ^a   Tanaka, Noriaki ^a   Nishibori, Masahiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

CD40; ICAM 1; IL 18; Monocytes; 1 antagonists

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; B7 ANTIGEN; BUNAZOSIN; CASPASE INHIBITOR; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CELL ADHESION MOLECULE; DOXAZOSIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; MONOCLONAL ANTIBODY; PRAZOSIN; QUINAZOLINE DERIVATIVE; TERAZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; CD86 PROTEIN, HUMAN; DRUG DERIVATIVE; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; SERINE PROTEINASE INHIBITOR; TERAZOSINE; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; TYROSYL VALYL ALANYL ASPARTIC ACID FLUOROMETHYL KETONE; TYROSYL-VALYL-ALANYL-ASPARTIC ACID FLUOROMETHYL KETONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CELL COMMUNICATION; CELL INTERACTION; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; T LYMPHOCYTE ACTIVATION; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM;

ADRENERGIC ALPHA-ANTAGONISTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; CD40 LIGAND; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXAZOSIN; FLOW CYTOMETRY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-18; MEMBRANE GLYCOPROTEINS; MOLECULAR STRUCTURE; MONOCYTES; PRAZOSIN; QUINAZOLINES; RECEPTORS, ADRENERGIC, ALPHA-1; SERINE PROTEINASE INHIBITORS; TOSYLPHENYLALANYL CHLOROMETHYL KETONE;

EID: 19944428889     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200501000-00005     Document Type: Article

References (22)

1. Osaki T, Peron JM, Cai Q, et al. IFN-γ-inducing factor/IL-18 administration mediates lFN-γ- and IL-12-independent antitumor effects. J Immunol. 1998;160:1742-1749.
2. Gu Y, Kuida K, Tsutsui H, et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science. 1997;275:206-209.
3. Kohno K, Kataoka J, Ohtsuki T, et al. IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol. 1997;158:1541-1550.
4. Takahashi HK, Iwagaki H, Yoshino T, et al. Prostaglandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells. J Immunol. 2002;168:4446-4454.
5. Takahashi HK, Iwagaki H, Mori S, et al. β2-adrenergic receptor agonist induces IL-18 production without IL-12 production. J Neuroimmunol. 2004;151:137-147.
6. Kohka H, Nishibori M, Iwagaki H, et al. Histamine is a potent inducer of IL-18 and IFN-gamma in human peripheral blood mononuclear cells. J Immunol. 2000;164:6640-6646.
7. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate hypertension: a double-blind, placebo-controlled, dose response multicenter study. J Urol. 1995;154:110-115.
8. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. N Engl J Med. 1996;335:533-539.
9. Young RA, Brogden RM. Doxazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. Drugs. 1988;35:525-541.
10. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by alpha 1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 2000;60:4550-4555.
11. Thebault S, Roudbaraki M, Sydorenko V, et al. Alpha 1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells. J Clin Invest. 2003;111:1691-1701.
12. Takeda K, Tsutsui H, Yoshimoto T, et al. Defective NK cell activity and ThI response in IL-18-deficient mice. Immunity. 1998;8:383-390.
13. Micallef MJ, Yoshida K, Kawai S, et al. In vivo antitumor effects of murine interferon-g-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother. 1997;43:361-367.
14. Tahmatzopoulos A, Kyprianou N. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Prostate. 2004;59:91-100.
15. Partin JV, Anglin IE, Kyprianou N. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer. 2003;88:1615-1621.
16. Benning CM, Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor- independent action. Cancer Res. 2002;62:597-602.
17. Shaw YJ, Yang YT, Garrison JB, et al. Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J Med Chem. 2004;47:4453-4462.
18. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
19. Colucci WS, Brock TA, Atkinson WJ, et al. Cultured vascular smooth muscle cells: an in vitro system for study of alpha-adrenergic receptor coupling and regulation. Cardiovasc Pharmacol. 1985;7(Suppl 6):S79-S86.
20. Colucci WS, Brock TA, Gimbrone MA Jr, et al. Regulation of alpha 1-adrenergic receptor-coupled calcium flux in cultured vascular smooth muscle cells. Hypertension. 1984;6:I19-I24.
21. Vincent J, Dachman W, Blaschke TF, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992;90:1763-1768.
22. Kaye B, Cussans NJ, Faulkner JK, et al. The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br J Clin Pharmacol. 1986;21:19S-25S.